Legend Biotech Corporation
- LEGN
- NASDAQ
- Biotechnology
- CAR-T Cell Therapy
$18.65
Today +0.92%Quote Oct 19, 2026, 08:00 PM UTC
+5.91%over the last month
Max drawdown −10.5%From 1-month high −6.2%3 months −20.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Legend Biotech
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
3,200
Founded
2014
Market value
$6.90B
Quote Oct 19
Floor
$18.04
3.3% below price
Resistance
$18.65
0.0% above price
Price vs analyst targets
20 analysts
Lowest target
$40.00Highest target
$78.00
$40.00Highest target
$78.00
- Price $18.65
- Average target $61.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 227% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LEGNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free